Cancer risk in individuals with benign thyroid disorders

被引:53
作者
Mellemgaard, A
From, G
Jorgensen, T
Johansen, C
Olsen, JH
Perrild, H
机构
[1] Danish Canc Soc, Div Canc Epidemiol, Copenhagen, Denmark
[2] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Bispebjerg Hosp, Dept Internal Med, Copenhagen, Denmark
[4] Bispebjerg Hosp, Dept Surg, Copenhagen, Denmark
关键词
D O I
10.1089/thy.1998.8.751
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of cancer was examined in a cohort of 57,326 individuals who were discharged from a Danish hospital with a diagnosis of myxedema, thyrotoxicosis, or goiter. Although the general risk of cancer was only slightly increased, the risk of several sites was significantly above expected. The risk of thyroid cancer especially, was increased with standardized incidence ratios among women of 2.1 (myxedema), 2.5 (thyrotoxicosis), and 6.6 (nontoxic goiter). The increase in risk was present even many years after discharge, indicating that surveillance was not the only explanation. Furthermore, an increased risk was noted for cancer of the kidney in women discharged with myxedema (standardized incidence ratios [SIR] = 1.8) and thyrotoxicosis (SIR = 1.3), for cancer of the bladder in women discharged with myxedema (SIR = 1.5) and nontoxic goiter (SIR = 1.3), and for cancer of the hematopoetic system in women discharged with myxedema (SIR = 1.4) and nontoxic goiter (SIR = 1.4). The findings indicate that thyroid disorders may be related to cancer risk of several specific sites other than the thyroid.
引用
收藏
页码:751 / 754
页数:4
相关论文
共 20 条
[1]  
[Anonymous], 1987, Statistical methods in cancer research, Vol 1-The analysis of case-control studies
[2]  
BEHAR R, 1986, SURGERY, V100, P1121
[3]   CANCER RISK IN PATIENTS WITH COLD THYROID-NODULES - RELEVANCE OF IODINE INTAKE, SEX, AGE, AND MULTINODULARITY [J].
BELFIORE, A ;
LAROSA, GL ;
LAPORTA, GA ;
GIUFFRIDA, D ;
MILAZZO, G ;
LUPO, L ;
REGALBUTO, C ;
VIGNERI, R .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 (04) :363-369
[4]  
Bertelsen J B, 1995, Ugeskr Laeger, V157, P4019
[5]  
CHOU FF, 1993, INT SURG, V78, P343
[6]  
GOLDMAN MB, 1990, CANCER RES, V50, P2283
[7]  
GOLDMAN MB, 1992, ONCOLOGY-BASEL, V49, P461
[8]   CANCER INCIDENCE FOLLOWING TREATMENT OF HYPERTHYROIDISM [J].
HOFFMAN, DA ;
MCCONAHEY, WM ;
FRAUMENI, JF ;
KURLAND, LT .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1982, 11 (03) :218-224
[9]   CANCER RISK AFTER I-131 THERAPY FOR HYPERTHYROIDISM [J].
HOLM, LE ;
HALL, P ;
WIKLUND, K ;
LUNDELL, G ;
BERG, G ;
BJELKENGREN, G ;
CEDERQUIST, E ;
ERICSSON, UB ;
HALLQUIST, A ;
LARSSON, LG ;
LIDBERG, M ;
LINDBERG, S ;
TENNVALL, J ;
WICKLUND, H ;
BOICE, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (15) :1072-1077
[10]  
HOLM LE, 1991, CANCER DETECT PREV, V15, P27